Dancann Pharma (DANCAN) Q3 2025 earnings summary

Executive summary

• Q3 2025 marked by organizational changes, including the CEO stepping down and a new interim CEO appointed, with a permanent successor planned.

• The company is focused on profitability, operational efficiency, and capital discipline amid ongoing market stabilization.

• Active divestment process for the Biotech Pharm 1 (BP1) facility continues, with interest from several parties.

Financial highlights

• Net sales for Q3 2025 were DKK 1,618 thousand, down from DKK 1,855 thousand in Q3 2024.

• EBITDA for Q3 2025 was DKK -1,038 thousand, compared to DKK -901 thousand in Q3 2024.

• Operating profit (EBIT) for Q3 2025 was DKK -1,535 thousand, versus DKK -1,420 thousand in Q3 2024.

• Cash flow for Q3 2025 was DKK -1,110 thousand, compared to DKK 5,748 thousand in Q3 2024.

• Equity at period end was DKK 7,064 thousand, down from DKK 13,310 thousand a year earlier.

Outlook and guidance

• The company remains committed to improving operational performance and achieving sustainable earnings over time.

• Focus areas include executing the Maturity 2028 strategy and managing the voluntary delisting process.